A T Cell‐Engaging Tumor Organoid Platform for Pancreatic Cancer Immunotherapy

A T Cell‐Engaging Tumor Organoid Platform for Pancreatic Cancer Immunotherapy

Abstract Pancreatic ductal adenocarcinoma (PDA) is a clinically challenging disease with limited treatment options. Despite a small percentage of cases with defective mismatch DNA repair (dMMR), PDA is included in the most immune‐resistant cancer types that are poorly responsive to immune checkpoint...

Full description

Bibliographic Details
Main Authors: Zhuolong Zhou, Kevin Van der Jeught, Yujing Li, Samantha Sharma, Tao Yu, Ishara Moulana, Sheng Liu, Jun Wan, Paul R. Territo, Mateusz Opyrchal, Xinna Zhang, Guohui Wan, Xiongbin Lu
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:Advanced Science
Subjects:
epigenetic inhibitors
high‐throughput drug screen
immunotherapy
pancreatic ductal adenocarcinoma
patient‐derived organoid
tumor antigen presentation
Online Access:https://doi.org/10.1002/advs.202300548

Internet

https://doi.org/10.1002/advs.202300548

Similar Items